References
- Woodcock J. The concept of pharmaceutical quality. American Pharmaceutical Review. 2004;47(6):1–3.
- Yu LX. Pharmaceutical quality by design: product and process development, understanding, and control. Pharm Res. 2008;25(4):781–791.
- Lionberger RA, Lee SL, Lee L, Raw A, Yu LX. Quality by design: concepts for ANDAs. AAPS J. 2008;10(2):268–276.
- Yu LX, Amidon G, Khan MA, et al. Understanding pharmaceutical quality by design. AAPS J. 2014;16(4):771–783.
- Boix-Montanes A. Relevance of equivalence assessment of topical products based on the dermatopharmacokinetics approach. Eur J Pharm Sci. 2011;42(3):173–179.
- Chang R-K, Raw A, Lionberger R, Yu L. Generic development of topical dermatologic products: formulation development, process development, and testing of topical dermatologic products. AAPS J. 2013;15(1):41–52.
- Lionberger RA. FDA critical path initiatives: opportunities for generic drug development. AAPS J. 2008;10(1):103–109.
- Weinberg S, Fuqua F. A stochastic model of “quality by design” for the pharmaceutical industry. Clayton State University, 2010. Available from: http://archives.pittcon.org/PittconWeb2010/attendee/pdf/2010/weinberg.pdf.
- IBM Business Consulting Services. Transforming industrialization: a new paradigm for pharmaceutical development, 2005. Available from: http://www-935.ibm.com/services/us/imc/pdf/ge510-3997-transforming-industrialization.pdf. Accessed May 26, 2015.
- International Conference on Harmonisation of Technical requirements for registration of pharmaceuticals for human use, Drafts Consensus Guideline, Pharmaceutical Development Annex to Q8, Nov 2007. Available from: http://www.pmda.go.jp/ich/q/step3_q8-a_08_3_17e.pdf.
- US Food and Drug Administration. Guidance for industry: PAT – a framework for innovative pharmaceutical development, manufacturing, and quality assurance. September 2004. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070305.pdf. Accessed May 26, 2015.
- US Food and Drug Administration. Guidance for industry: Q9 quality risk management, ICH, June 2006. Available from: http://www.fda.gov/downloads/Drugs/…/Guidances/ucm073511.pdf. Accessed May 26, 2015.
- Rosas JG, Blanco M, González JM, Alcalá M. Quality by design approach of a pharmaceutical gel manufacturing process, part 1: determination of the design space. J Pharm Sci. 2011;100(10):4432–4441.
- Xie L, Wu H, Shen M, et al. Quality-by-design (QbD): effects of testing parameters and formulation variables on the segregation tendency of pharmaceutical powder measured by the ASTM D 6940-04 segregation tester. J Pharm Sci. 2008;97(10):4485–4497.
- Herkenne C, Alberti I, Naik A, et al. In vivo methods for the assessment of topical drug bioavailability. Pharm Res. 2008;25(1):87–103.
- US Food and Drug Administration. Guidance for industry: Q8 pharmaceutical development, ICH, May 2006. Available from: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4241B1-02-03-FDA-Q8%20Guidance%206746fnl.pdf. Accessed May 26, 2015.
- Chang R-K, Raw A, Lionberger R, Yu L. Generic development of topical dermatologic products. Part II: quality by design for topical semisolid products. AAPS J. 2013;15(3):674–683.
- Lionberger R. Quality by design for topical dosage forms. Office of Generic Drugs, US Food and Drug Administration, 2005. Available from: http://www.fda.gov/ohrms/dockets/ac/05/slides/2005-4137s2_04_lionberger.ppt.
- Shaw AS. Quality by sesign (QbD) for dermatologic products. Office of Generic Drugs, US Food and Drug Administration, 2013. Available from: http://www.pqri.org/workshops/Topicals2013/Raw.pdf. Accessed May 26, 2015.
- United States Pharmacopeia (USP) 29-NF 24 Vol 36 (6) [Nov–Dec 2010] page 2499. Available from: http://www.pharmacopeia.cn/v29240/usp29nf24s0_c51.html. Accessed May 26, 2015.
- Lowenborg M. A troubleshooting guide for topical drug manufacturing. Pharmaceutical Technology. 2012;36:46–49.
- Shah VP, Flynn GL, Yacobi A, et al. Bioequivalence of topical dermatological dosage forms – methods of evaluation of bioequivalence. Pharm Res. 1998;15(2):167–171.
- Narkar Y. Bioequivalence for topical products – an update. Pharm Res. 2010;27(12):2590–2601.
- US Food and Drug Administration. Guidance for industry, nonsterile semisolid dosage forms, scale-up and post approval changes: in vitro release testing and in vivo bioequivalence documentation, May 7, 1997. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070930.pdf. Accessed May 26, 2015.
- Buhse L, Kolinski R, Westenberger B, et al. Topical drug classification. Int J Pharm. 2005;295(1–2):101–112.